Skip to main content
    C

    Cogent Biosciences Inc (COGT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $31.64
    +2.07 (+6.98%)

    Market Cap: $5.13B

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    34%(12/35)
    Avg Surprise
    -52.72%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.56
    Range$-0.88 - $-0.26
    9 analysts
    Revenue Consensus
    $6M
    Range$0 - $14M
    11 analysts
    Last 12 of 38 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.56$-0.88 - $-0.26--9--
    Sep 26
    Reported Nov 5
    		$-0.59$-0.57$-0.64 - $-0.45-3.51%Miss8
    5
    1
    30d
    		-18.0%
    Jun 26
    Reported Aug 10
    		$-0.52$-0.55$-0.66 - $-0.49+5.45%Beat10
    2
    4
    30d
    		+1.9%
    Mar 26
    Reported May 5
    		$-0.53$-0.50$-0.66 - $-0.46-5.66%Miss8
    1
    3
    30d
    		-1.0%
    Dec 25
    Reported Feb 17
    		$-0.56$-0.51$-0.60 - $-0.41-9.80%Miss12
    1
    0
    30d
    		-522.2%
    Sep 25
    Reported Nov 7
    		$-0.50$-0.52$-0.59 - $-0.42+3.85%Beat12
    5
    3
    30d
    		+21.9%
    Jun 25
    Reported Aug 5
    		$-0.53$-0.58$-0.66 - $-0.38+8.62%Beat11
    1
    2
    30d
    		+10.2%
    Mar 25
    Reported May 6
    		$-0.52$-0.58$-0.65 - $-0.44+9.05%Beat7
    1
    0
    30d
    		+15.3%
    Dec 24
    Reported Feb 25
    		$-0.09N/A-+84.48%Beat9
    4
    5
    30d
    		+85.7%
    Sep 24
    Reported Nov 12
    		$-0.64$-0.57$-0.67 - $-0.44-12.28%Miss11
    No revisions (30d)
    		+0.0%
    Jun 24
    Reported Aug 6
    		$-0.59$-0.55$-0.66 - $-0.33-7.27%Miss10
    No revisions (30d)
    		+0.0%
    Mar 24
    Reported May 7
    		$-0.62$-0.51$-0.59 - $-0.40-21.57%Miss9
    No revisions (30d)
    		-8.8%
    Dec 23
    Reported Feb 26
    		$-0.63$-0.56$-0.66 - $-0.37-12.50%Miss11
    No revisions (30d)
    		-12.5%

    Key Metrics

    Valuation
    P/E Ratio-14.38EV/EBITDAN/A
    Price/FCF-17.50xFCF Yield-5.71%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-109.70%ROIC-39.28%
    Financial Health
    Debt/Equity0.42xInterest Coverage-72.72x
    Current Ratio13.57xQuick Ratio13.57x
    Trading Statistics
    Beta0.34Avg Volume2.23M
    52-Week High$43.7352-Week Low$27.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$31.16
    SMA 20$30.59
    SMA 50$31.82
    SMA 200$35.48
    EMA 10$30.96
    EMA 20$31.01
    EMA 50$32.15
    EMA 200$32.72

    MACD

    Line: -0.21Signal: -0.33Hist: 0.12

    ADX

    ADX: 18.5+DI: 15.7-DI: 19.7

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down32.0
    PSAR$32.53

    Bollinger Bands

    Upper Band$33.04
    Lower Band$28.15
    %B Position1596%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    52.1

    Momentum Oscillators

    Stoch %K48.9
    Stoch %D50.1
    Williams %R-31.2
    ROC (10d)1.4%
    Momentum0.43
    CCI (20d)14.1
    MFI (14d)57.7

    Volatility Measures

    ATR (14d)$1.54(4.9%)
    StdDev (20d)1.22
    Hist Vol56.3%(High)

    Volume Flow

    VWAP$30.77
    OBV98.6M
    AD Line32.3M
    CMF (20d)0.004

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio0.7x
    VWMA (20d)$30.41

    Pivot Points

    R3$33.20
    R2$32.30
    R1$30.94
    Pivot Point$30.05
    S1$28.69
    S2$27.79
    S3$26.43

    Advanced Oscillators

    TSI-4.52
    Ultimate Osc51.7
    KST-7.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$4.29M$0$0$0$5.59M$0
    Cost of RevenueN/A$1.16M$1.18MN/A$1.16M$1.14MN/A$1.10M$1.08M$1.07M$794,000$855,000
    Gross ProfitN/A$-1,155,000$-1,177,000N/A$-1,157,000$-1,138,000$2.15M$-1,097,000$-1,080,000$-1,066,000$4.79M$-855,000
    Operating Expenses$102.64M$102.45M$98.32M$83.36M$74.42M$74.93M$73.73M$75.41M$64.39M$62.40M$58.23M$59.58M
    R&D$70.81M$75.36M$74.38M$68.99M$61.05M$63.03M$62.05M$63.61M$54.29M$52.70M$48.72M$50.13M
    SG&A$31.83M$28.24M$23.93M$14.37M$13.38M$11.90M$11.69M$11.80M$10.09M$9.70M$9.51M$9.45M
    Operating Income$-102,638,000$-103,607,000$-99,493,000$-83,355,000$-75,582,000$-74,933,000$-73,734,000$-75,414,000$-64,387,000$-62,404,000$-58,228,000$-59,580,000
    Interest Income$7.46M$7.61M$5.48M$3.89M$2.37M$2.95M$3.86M$4.78M$5.39M$4.06M$3.87M$4.20M
    Interest Expense$1.22M$1.21M$1.29M$1.46M$314,000$0$0$0$0$0$4.65M$0
    Income Before Tax$-96,405,000$-97,352,000$-102,492,000$-80,930,000$-73,529,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-4,057,000$-3,870,000$-855,000
    Net Income$-96,405,000$-97,352,000$-102,492,000$-80,930,000$-73,529,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    EBITDA$-94,447,000$-94,984,000$-104,603,000$-78,324,000$-72,058,000$-70,848,000$-66,819,000$-69,537,000$-57,870,000$-57,282,000$-53,571,000$-54,527,000
    EBIT$-95,188,000$-96,139,000$-105,744,000$-79,471,000$-73,215,000$-71,986,000$-67,927,000$-70,634,000$-58,950,000$-58,348,000$-54,365,000$-55,382,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about COGT

    News

    Cogent Biosciences (COGT) Could Be 89% Undervalued On Wider Third Quarter Losses

    Cogent Biosciences (COGT) reported wider third-quarter 2026 losses, reaching US$111.43 million, yet a Discounted Cash Flow (DCF) model suggests the stock might be significantly undervalued by 89% compared to its...

    Simply Wall St•11/5/26•Somewhat-Bearish

    With $791M in cash and securities, Cogent Biosciences (COGT) posts a wider quarterly loss.

    Cogent Biosciences reported a wider net loss of $111.4 million for the third quarter of 2026, compared to $80.9 million a year prior...

    Stock Titan•11/5/26•Neutral

    Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

    Cogent Biosciences reported its third-quarter 2026 financial results, highlighting preparations for the anticipated launch of bezuclastinib in GIST and other systemic mastocytosis indications. The company has a strong...

    GlobeNewswire•11/5/26•Bullish

    Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

    Cogent Biosciences reported its third-quarter 2026 financial results, with a widened net loss of $111.4 million...

    Stock Titan•11/5/26•Neutral

    (COGT) and the Role of Price-Sensitive Allocations

    This article provides an in-depth analysis of Cogent Biosciences Inc. (NASDAQ: COGT) based on AI-generated signals and institutional trading strategies. It highlights conflicting sentiment across different time horizons...

    Stock Traders Daily•11/4/26•Somewhat-Bullish

    COGT Valuation and Fair Value

    P/E
    -14.4x
    P/FCF
    -17.5x
    P/B
    10.2x
    See GNG's fair value

    COGT Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -39.3%
    ROE
    -109.7%
    FCF yield
    -5.7%

    COGT Competitors

    CompanyTicker
    LivaNova PLCLIVN
    Lifestance Health Group IncLFST
    GRAIL, LLCGRAL
    Crispr Therapeutics AGCRSP
    Merit Medical Systems IncMMSI
    Terns Pharmaceuticals IncTERN
    Concentra Group Holdings Parent, Inc.CON
    Diversified Healthcare TrustDHCNL

    Sector: Healthcare

    COGT Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    2
    Buy
    9
    Hold
    1
    Sell
    0
    Strong Sell
    0

    COGT Bull Case vs Bear Case

    Bull case

    • 91.7% of COGT's analyst ratings are Buy or Strong Buy.

    Bear case

    • COGT's quarterly revenue changed -100.0% year over year.

    COGT Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    11.6%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.56

    COGT Earnings Date

    COGT reports Feb 15, 2027, after the close. The date is estimated.

    COGT ETF Holders

    GNG tracks 16 ETFs that hold COGT. The largest weights:

    1. State Street SPDR S&P Biotech ETF (XBI), 1.22% of the fund
    2. abrdn Healthcare Investors (HQH), 0.59% of the fund
    3. BlackRock Health Sciences Trust (BME), 0.52% of the fund
    4. iShares Biotechnology ETF (IBB), 0.35% of the fund
    5. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.19% of the fund
    Open the ETF Stock Exposure tool for COGT

    See insider activity

    Frequently Asked Questions About COGT

    When does COGT report earnings?

    Cogent Biosciences Inc (COGT) is expected to report earnings on Feb 15, 2027.

    Does COGT pay dividends?

    Cogent Biosciences Inc (COGT) does not currently pay a regular dividend.

    What is COGT's market cap?

    Cogent Biosciences Inc (COGT) has a market capitalization of $5.13B with a current stock price of $31.64.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In